Company Announcements

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK , March 16, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Aquestive's NDA for Anaphylm; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling.

On January 9, 2026, Aquestive's President and Chief Executive Officer announced that "[a]s part of its ongoing review of the Company's NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time," stating that "the notification did not specify the deficiencies[.]"

On this news, Aquestive's stock price fell $2.30 per share, or 37.04%, to close at $3.91 per share on January 9, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Aquestive's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Aquestive class action, go to www.faruqilaw.com/AQST or callFaruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aqst-investor-deadline-approaching-faruqi--faruqi-llp-reminds-aquestive-therapeutics-investors-of-securities-class-action-deadline-on-may-4-2026-302714963.html

SOURCE Faruqi & Faruqi, LLP